BACKGROUND: Maspin is a serpin family of protease inhibitors. Althouth maspin has been considered a tumor suppressor that inhibits the motility, invasion, and metastasis of breast and prostatic cancer cells, there are many conflicting reports about maspin expression and cancer prognosis. METHODS: To investigate whether the expression of maspin could be used as a prognostic marker in pancreatic cancer, 72 paraffin-embedded pancreatic ductal adenocarcinomas were analyzed using immunohistochemistry. We examined the prognostic value of maspin as well as its relationship with clinicopathological features. RESULTS: Maspin expression was observed in all pancreatic ductal adenocarcinoma. Unlike cancer tissues, however, faint or no expression was observed in the corresponding normal pancreatic tissues. In the Cox proportional hazard model, high maspin expression predicted a high hazard rate. Maspin expression had a positive correlation with tumor stage, but there were also no statistically significant relationships between maspin expression and other clinicopathological features. CONCLUSION: These findings suggest maspin expression to have biological relevance in the progression of pancreatic cancers, with potential use as a prognostic marker for pancreatic neoplasm with epithelial origin.
BACKGROUND:Maspin is a serpin family of protease inhibitors. Althouth maspin has been considered a tumor suppressor that inhibits the motility, invasion, and metastasis of breast and prostatic cancer cells, there are many conflicting reports about maspin expression and cancer prognosis. METHODS: To investigate whether the expression of maspin could be used as a prognostic marker in pancreatic cancer, 72 paraffin-embedded pancreatic ductal adenocarcinomas were analyzed using immunohistochemistry. We examined the prognostic value of maspin as well as its relationship with clinicopathological features. RESULTS:Maspin expression was observed in all pancreatic ductal adenocarcinoma. Unlike cancer tissues, however, faint or no expression was observed in the corresponding normal pancreatic tissues. In the Cox proportional hazard model, high maspin expression predicted a high hazard rate. Maspin expression had a positive correlation with tumor stage, but there were also no statistically significant relationships between maspin expression and other clinicopathological features. CONCLUSION: These findings suggest maspin expression to have biological relevance in the progression of pancreatic cancers, with potential use as a prognostic marker for pancreatic neoplasm with epithelial origin.
Authors: M M Le Beau; J Overhauser; R E Straub; G Silverman; T C Gilliam; J Ott; P O'Connell; U Francke; A Geurts van Kessel Journal: Cytogenet Cell Genet Date: 1993
Authors: P A Pemberton; A R Tipton; N Pavloff; J Smith; J R Erickson; Z M Mouchabeck; M C Kiefer Journal: J Histochem Cytochem Date: 1997-12 Impact factor: 2.479
Authors: Z Zou; A Anisowicz; M J Hendrix; A Thor; M Neveu; S Sheng; K Rafidi; E Seftor; R Sager Journal: Science Date: 1994-01-28 Impact factor: 47.728
Authors: Chenxi Tian; Daniel Öhlund; Steffen Rickelt; Tommy Lidström; Ying Huang; Liangliang Hao; Renee T Zhao; Oskar Franklin; Sangeeta N Bhatia; David A Tuveson; Richard O Hynes Journal: Cancer Res Date: 2020-02-06 Impact factor: 12.701
Authors: Seong Man Kim; Seong Jin Cho; Woo Young Jang; Duck Hwan Kim; Hyung Sik Shin; Myoung Kuk Jang; Hak Yang Kim; Eun Sook Nam Journal: Cancer Res Treat Date: 2005-08-31 Impact factor: 4.679
Authors: Asif Ali; Victoria Brown; Simon Denley; Nigel B Jamieson; Jennifer P Morton; Colin Nixon; Janet S Graham; Owen J Sansom; C Ross Carter; Colin J McKay; Fraser R Duthie; Karin A Oien Journal: BMC Clin Pathol Date: 2014-07-23
Authors: Manoj K Bhasin; Kenneth Ndebele; Octavian Bucur; Eric U Yee; Hasan H Otu; Jessica Plati; Andrea Bullock; Xuesong Gu; Eduardo Castan; Peng Zhang; Robert Najarian; Maria S Muraru; Rebecca Miksad; Roya Khosravi-Far; Towia A Libermann Journal: Oncotarget Date: 2016-04-26